Correlation of gut microbiota with leukopenia after chemotherapy in patients with colorectal cancerOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether gut microbiota composition correlates with leukopenia (low white blood cell count) after chemotherapy in colorectal cancer (CRC) patients. Leukopenia reflects chemotherapy-induced bone marrow suppression. Fecal microbiota was profiled by 16S rRNA sequencing of the V3-V4 region on a MiSeq platform, with alpha-diversity, LEfSe, and correlation analyses. Six machine-learning algorithms, including logistic regression, random forest, neural network, support vector machine, gradient boosting, and CatBoost, were used to build prediction models.
Who was studied?
The cohort was 55 CRC patients receiving first-time chemotherapy and 56 healthy volunteers at Huzhou Central Hospital in China, sampled between 2019 and 2021. By post-chemotherapy white blood cell level, patients were split into a hypoleukocytes group (n=13, below 3.5 x10^9/L) and a normal leukocytes group (n=42). CRC was pathologically confirmed, and patients with prior chemotherapy, other tumors, or recent microbiota preparations were excluded. Healthy controls skewed younger than patients.
What were the most important findings?
CRC patients had significantly lower gut microbial diversity than healthy controls, though total abundance did not differ. Fifteen differential taxa were found, including Bacteroides, Faecalibacterium, and Streptococcus. Within CRC, the hypoleukocytes group had significantly lower diversity than the normal group, and Escherichia-Shigella was reduced. Nine differential taxa separated the groups, such as Fusicatenibacter and Cetobacterium. For leukopenia prediction, random forest reached AUC 0.995 and CatBoost gave the best accuracy (sensitivity 85.17 percent, specificity 100 percent). The most predictive taxa were Fusicatenibacter, Cetobacterium, and Paraeggerthella.
What are the greatest implications of this study?
The results suggest gut microbiota is associated with chemotherapy-induced leukopenia in CRC and could help predict which patients are at high risk, enabling earlier preventive measures like leukocyte support or dose adjustment. Distinct microbial signatures for CRC and for post-chemotherapy leukopenia may offer non-invasive biomarkers. The authors note the small sample, the age gap between younger controls and older patients, and that whether these bacterial shifts cause or result from low white cell counts remains unknown. Larger studies are needed.